---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-015157"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2023-01-25T23:59:59+00:00"
generated_at: "2026-06-20T09:29:59.423580+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Galera Therapeutics regains compliance with Nasdaq MVLS requirement, delisting avoided

## Summary
- Received Nasdaq letter confirming compliance with $50M MVLS requirement for continued listing on Nasdaq Global Market.
- Hearing before Nasdaq Hearings Panel on Jan 26, 2023 cancelled.
- Company had previously been notified of non-compliance in Dec 2022 and appealed delisting.
- Common stock (GRTX) will continue trading on Nasdaq Global Market.

## SEC filing metadata
- accession: 0001193125-23-015157
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2023-01-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312523015157/0001193125-23-015157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312523015157/d441370d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-015157
- JSON: https://secwatch.observer/filing/0001193125-23-015157.json
- Plain text: https://secwatch.observer/filing/0001193125-23-015157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.